Nateghpour M M, Edrissian Gh, Torabi A, Raesi A, Motevalli-Haghi H, Abed-Khojasteh N, Ghobakhlo N,
Volume 67, Issue 3 (6-2009)
Abstract
Normal
0
false
false
false
EN-GB
X-NONE
AR-SA
MicrosoftInternetExplorer4 !mso]>
ject classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui>
Background: Malaria is an
important parasitic vector-borne disease with considerable infectivity and
world-wide distribution. Since prevalence of chloroquine resistance in Plasmodium
falciparum at the malarious areas such as Iran
and reliable reports from many countries indicating emergence of chloroquine-
resistant strains of P.vivax, this study was conducted to monitor the
current response of vivax and falciparum plasmodia to chloroquine
in Bandar-Abbas district, a malarious area in Iran.
Methods: The study was
conducted at the Bandar-Abbas district in Hormozgan province, Iran. 123 patients were
enrolled and considered. The patients were treated with a standard 3-day regimen of
chloroquine and were followed-up clinically and parasitologically. The results
were interpreted as mean parasite clearance time (MPCT) in P. vivax and early
treatment failure (ETF), late treatment failure (LTF) and adequate clinical and parasitological response (ACPR) in P. falciparum.
Results: The patients with
vivax malaria were responded to the regimen of chloroquine within 24-216 hours. Most cases of
the parasite clearance time occurred at 48 hours (50.40%), and less of them at 120, 168, 192 and 216 hours with 0.81% for each of them. MPCT in this study was
calculated as 61.07 (±26/47) hours for all of the patients. 33.33% and 66.66% of the patients with falciparum malaria
were found at ACPR
and LTF groups, respectively.
Conclusion: This study confirms the efficacy of chloroquine on P.vivax.
The extended parasite clearance time in a number of patients may be an early
sign for reduced susceptibility of P.vivax to chloroquine in the studied
areas. Most of the patients with falciparum malaria (66.66%)
considered in this study did not respond to the regimen of chloroquine because
of chloroquine- resistance in P.falciparum at the area.